CO6361935A2 - Inhibidores de glicógeno sintasa cinasa-3 beta que contienen derivados de 7-hidroxi-benzoimidazol-4-il-metanona - Google Patents

Inhibidores de glicógeno sintasa cinasa-3 beta que contienen derivados de 7-hidroxi-benzoimidazol-4-il-metanona

Info

Publication number
CO6361935A2
CO6361935A2 CO11061830A CO11061830A CO6361935A2 CO 6361935 A2 CO6361935 A2 CO 6361935A2 CO 11061830 A CO11061830 A CO 11061830A CO 11061830 A CO11061830 A CO 11061830A CO 6361935 A2 CO6361935 A2 CO 6361935A2
Authority
CO
Colombia
Prior art keywords
benzoimidazol
metanona
sintasa
cinasa
hidroxi
Prior art date
Application number
CO11061830A
Other languages
English (en)
Inventor
Yo Matsuo
Ryuji Ahsawa
Shoji Hisada
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of CO6361935A2 publication Critical patent/CO6361935A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan inhibidores GSK-3beta que comprenden derivados de 7-hidroxi-benzoimidazol-4-il-metanona. Por ejemplo los inhibidores que tienen la siguiente fórmula general (I)
CO11061830A 2008-11-20 2011-05-19 Inhibidores de glicógeno sintasa cinasa-3 beta que contienen derivados de 7-hidroxi-benzoimidazol-4-il-metanona CO6361935A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11654308P 2008-11-20 2008-11-20

Publications (1)

Publication Number Publication Date
CO6361935A2 true CO6361935A2 (es) 2012-01-20

Family

ID=42197956

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11061830A CO6361935A2 (es) 2008-11-20 2011-05-19 Inhibidores de glicógeno sintasa cinasa-3 beta que contienen derivados de 7-hidroxi-benzoimidazol-4-il-metanona

Country Status (15)

Country Link
US (1) US20110301146A1 (es)
EP (1) EP2358365A4 (es)
JP (1) JP2012509249A (es)
KR (1) KR20110086750A (es)
CN (1) CN102292083A (es)
AU (1) AU2009318719A1 (es)
BR (1) BRPI0920959A2 (es)
CA (1) CA2744012A1 (es)
CO (1) CO6361935A2 (es)
IL (1) IL212704A0 (es)
MX (1) MX2011005369A (es)
RU (1) RU2011124960A (es)
SG (1) SG171761A1 (es)
WO (1) WO2010058512A1 (es)
ZA (1) ZA201104487B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011001170A (es) * 2008-07-30 2011-04-05 Oncotherapy Science Inc Derivados de benzoimidazol e inhibidores de glucogeno sintasa cinasa 3-beta que contienen los mismos.
CN101619058A (zh) * 2009-01-08 2010-01-06 上海交通大学 一种苯并咪唑-4-酰胺型衍生物
MX2021011606A (es) 2019-04-02 2021-12-10 Aligos Therapeutics Inc Compuestos dirigidos a prmt5.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006515013A (ja) * 2003-01-23 2006-05-18 クリスタルジェノミクス、インコーポレイテッド グリコーゲン合成酵素キナーゼ３β活性抑制剤、組成物及びその製造方法
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
BRPI0919977A2 (pt) * 2008-10-30 2015-08-25 Oncotherapy Science Inc Derivados de 7-hidróxi-benzoimidazol-4-il-metanona e inibidores de pbk contendo os mesmos

Also Published As

Publication number Publication date
IL212704A0 (en) 2011-07-31
MX2011005369A (es) 2011-06-20
CN102292083A (zh) 2011-12-21
CA2744012A1 (en) 2010-05-27
JP2012509249A (ja) 2012-04-19
ZA201104487B (en) 2012-03-28
EP2358365A4 (en) 2012-05-30
EP2358365A1 (en) 2011-08-24
AU2009318719A1 (en) 2011-06-30
KR20110086750A (ko) 2011-07-29
US20110301146A1 (en) 2011-12-08
BRPI0920959A2 (pt) 2017-07-11
SG171761A1 (en) 2011-07-28
RU2011124960A (ru) 2012-12-27
WO2010058512A1 (en) 2010-05-27

Similar Documents

Publication Publication Date Title
CO6680675A2 (es) Tidiazoles substituidos y composiciones pesticidas que los contienen
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
DOP2015000264A (es) Derivados de azaadamantano y métodos de uso de los mismos
CR20120295A (es) Triazolopiridinas
CR20180057A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
SV2010003776A (es) Derivados de pirimidina como inhibidores de cinasa
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
CR20140135A (es) Nuevos derivados de aril-quinolina
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
CR11618A (es) Inhibidores macrocíclicos de serina proteasa
CL2012003104A1 (es) Compuestos derivados de multiheteroarilos, inhibidores de prostaglandina d sintasa hematopoyetica (h-pgds); y composicion farmaceutica que los comprende.
CL2012001821A1 (es) Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
CY1112465T1 (el) Παραγωγα αμινοτριαζολης ως αγωνιστες alx
UY32529A (es) Compuestos heterocíclicos y su uso como inhibidores de la glucógeno sintetasa quinasa 3
CR20120637A (es) Triazolopiridinas sustituidas
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
GT200900192A (es) Derivados de imidazol como inhibidores de proteina de uso de cinesina (eg-5).-
DOP2014000098A (es) 2-tiopirimidinonas
CU20100170A7 (es) Inhibidores heterocíclicos de estearoil-coa-desaturasa
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
EA200900631A1 (ru) Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена)
PA8792401A1 (es) Fenilendiaminas
DOP2012000260A (es) Uso de nuevos inhibidores de pan–cdk para tratar tumores

Legal Events

Date Code Title Description
FA Application withdrawn